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Abstract C2C12 cells are a well-established model system for
studying myogenesis. We examined whether inhibiting the
process of myogenesis via expression of dominant negative
(DN) mitogen-activated protein kinase kinase-3 (MKK3) facili-
tated the trans-differentiation of these cells into adipocytes. Cells
expressing DN MKK3 respond to rosiglitazone, resulting in
adipocyte formation. The effects of rosiglitazone appear to be
potentiated through peroxisome proliferator activating receptor-
Q. This trans-differentiation is inhibited by the use of the
phosphoinositide-3 (PI3) kinase inhibitor, LY294002. These
results indicate that preventing myogenesis through expression
of DN MKK3 facilitates adipocytic trans-differentiation, and
involves PI3 kinase signalling. ß 2001 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
Key words: Trans-di¡erentiation; Adipogenesis; Myogenesis;
C2C12; Mitogen-activated protein kinase kinase-3;
Peroxisome proliferator activating receptor-Q
1. Introduction
The formation of muscle, bone, and adipose tissue are com-
plex processes involving the determination of common precur-
sor cells towards speci¢c di¡erentiation pathways. A current
area of interest is the determination of factors that are able to
promote the transition between one di¡erentiated lineage to
another, in particular, the trans-di¡erentiation between
muscle and adipose tissue. The imbalance between adipose
and muscle mass is a hallmark of many disorders, including
type 2 diabetes, obesity, and sarcopenia [1^3]. Skeletal muscle
and adipose tissue are key players in the development of in-
sulin resistance, manifested by decreased insulin-stimulated
glucose transport and metabolism in these tissues [1]. It is
known that myogenic cell lines and muscle satellite cells are
capable of trans-di¡erentiating into adipocytes, among other
cell types [4,5]. Thus, the study of trans-di¡erentiation of
muscle tissue into fat is highly applicable to the study of
disorders where muscle atrophy and increase in adipose tissue
mass are correlated.
The development of skeletal muscle is controlled by the
muscle regulatory factors, such as myf-5 [6], myogenin [7],
and MyoD [8]. Fusion of myocytes into multinucleated myo-
tubes is the terminal step of muscle di¡erentiation. In vitro,
the major steps in muscle di¡erentiation can be reproduced
with myoblastic cell lines such as C2C12 murine myoblast
cells [9]. Di¡erentiation of adipocytes appears to be controlled
by peroxisome proliferator activating receptor-Q (PPARQ) and
the C/EBP families of transcription factors [10]. PPARQ, a
nuclear hormone receptor, is expressed primarily in adipose
tissue, and is induced early in the process of adipose di¡er-
entiation [10]. Fatty acids, as well as the insulin-sensitizing
agents thiazolidinediones, are known to promote adipogenesis
by activating PPARQ [11,12]. This results in the upregulation
of adipocyte-speci¢c genes such as adipocyte lipid-binding
protein 2 (aP2), Glut4, and fatty acid transporter [10,13].
The mitogen-activated protein (MAP) kinase signalling
pathways are crucial for the processes of myogenesis and adi-
pogenesis, in particular, the MAP kinase kinase-3 (MKK3)/
p38 pathway [14,15]. However, little is known regarding the
roles of these signalling pathways in the trans-di¡erentiation
of myoblasts to adipocytes. In this study, we report that
blocking myotube formation in C2C12 cells via the expression
of dominant negative (DN) MKK3 enables these cells to
trans-di¡erentiate into adipocytes in response to rosiglitazone.
In addition, we show that the process of trans-di¡erentiation
in these cells is characterized by upregulation of PPARQ, and
involves the kinase phosphoinositide-3 (PI3) kinase pathway.
2. Materials and methods
2.1. Chemicals and materials
Cell culture reagents were purchased from Life Technologies (Cergy
Pontoise, France). SB203580 was obtained from Calbiochem (La Jol-
la, CA, USA), and LY294002 and insulin from Sigma (Saint Quentin
Fallavier, France). Rosiglitazone (CD3145 or BRL49653) was ob-
tained from Galderma (France). The mouse monoclonal anti-myoge-
nin antibody was purchased from Pharmingen (Le Pont de Claix,
France). The anti-aP2 rabbit polyclonal antibody was a gift of Dr.
David Bernlohr (University of Minnesota, St. Paul, MN, USA).
2.2. Cell culture and rosiglitazone treatment
Mouse C2C12 myoblasts (ATCC number CRL-1772) were cultured
at 37‡C in an atmosphere of 5% CO2 in growth medium consisting of
Dulbecco’s modi¢ed Eagle’s medium supplemented with 10% fetal calf
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serum and 1% v/v penicillin/streptomycin. The DN MKK3 C2C12 cell
line has been previously described [16]. To induce trans-di¡erentia-
tion, cells were placed in medium containing rosiglitazone (concentra-
tions stated in ¢gure legends) 2 days before con£uence, and main-
tained up to 5 days post-con£uence. All experiments were
performed using three separate clones of each cell line.
2.3. Western blots
Cells were treated as indicated in the ¢gures, rinsed, and proteins
were solubilized in ice-cold lysis bu¡er (50 mM HEPES, pH 7.4, 150
mM NaCl, 100 mM NaF, 10 mM EDTA, 10 mM Na4P2O7, 2 mM
Na3VO4, 1% Triton X-100, and supplemented with protease inhibi-
tors: aprotinin (2 Wg/ml), leupeptin (10 WM) and AEBSF (1 mM)).
Equal amounts of protein were separated by SDS^PAGE on a 10%
acrylamide gel. Proteins were transferred to Hybond-C Extra mem-
brane (Amersham), and the membranes were blocked for 1 h at room
temperature in TBS, 0.1% Tween 20, 5% bovine serum albumin
(BSA). The membranes were washed in wash bu¡er (TBS, 0.1%
Tween 20) for 30 min, probed with the primary antibody and then
secondary antibody for 1 h in TBS, 0.1% Tween 20, 1% BSA. After
each incubation, membranes were washed for 30 min with three
changes of wash bu¡er. Proteins were visualized using the Amersham
ECL0 system. Blots were scanned and quanti¢cation was performed
using PCBas0.
2.4. Northern blots
RNA was isolated using the Tri-Insta Pure0 kit (Eurogentec,
France), according to manufacturer’s directions. Northern blots
were performed as previously described [17]. The ¢lters were probed
using a labelled, full-length PPARQ cDNA, as described in [18].
2.5. Oil red O staining
Oil red O staining was performed as previously described [17]. Cells
were photographed using a Nikon Coolpix 990 digital camera
mounted on a Leitz Wetzlar light microscope.
3. Results
3.1. C2C12 cells expressing DN MKK3 trans-di¡erentiate into
adipocytes upon treatment with rosiglitazone
We have previously shown that expression of DN MKK3
inhibits myotube formation and results in signi¢cantly de-
creased p38 activity [16]. We were interested in determining
whether blocking myogenesis in C2C12 cells in this manner
enabled the trans-di¡erentiation of these cells into other line-
ages. Control experiments were performed using wild-type
untransfected cells, as well as the empty vector control cell
line. All experiments were performed using three separate
clones of each cell line, including the DN MKK3 C2C12
line. Representative results are shown in the ¢gures. To induce
adipogenesis, we used rosiglitazone (also known as CD3145 or
BRL49653), a speci¢c PPARQ ligand able to induce adipo-
genesis in a variety of cell types, including myocytes [19].
The glitazones are known agonists of PPARQ, a master gene
involved in the regulation of adipocyte-speci¢c gene expres-
sion [11].
Treatment of DN MKK3 C2C12 cells with rosiglitazone
resulted in the di¡erentiation of adipocytes after 5 days
(Fig. 1). In keeping with previous results on this cell line,
the DN MKK3 C2C12 cells did not di¡erentiate into myo-
Fig. 1. MKK3 DN C2C12 cells di¡erentiate into adipocytes upon treatment with rosiglitazone (BRL). Control and MKK3 DN C2C12 cells
were grown in growth media, and treated with 5 WM rosiglitazone 2 days before con£uence. The cells were maintained in medium containing
rosiglitazone for up to 5 days post-con£uence. Insets depict Oil red O staining at 5 days post-con£uence. Arrows indicate the location of oil
droplets. Scale bar = 10 Wm.
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tubes [14,16]. Control cells di¡erentiated mainly into myo-
tubes, whereas the DN MKK3 line displayed areas of
rounded cells that contained lipid droplets. The rounded, lip-
id-containing cells appeared in clusters throughout the con£u-
ent monolayer of DN MKK3 cells beginning at 3 days post-
con£uence, with the number of adipocytic cells increasing
over time. Oil red O staining for neutral triglycerides revealed
only a few oil droplets in the control cells, whereas the DN
MKK3 cells exhibited large regions of cells containing oil
droplets. Representative ¢elds are depicted in Fig. 1.
3.2. Upregulation of PPARQ mRNA and the aP2 protein in the
DN MKK3 cells upon rosiglitazone treatment
Since PPARQ is known to play a major role in regulating
adipogenesis, we examined whether this gene was upregulated
in the DN MKK3 C2C12 cells. We performed Northern blots
using RNA harvested from control and DN MKK3 cells
treated with rosiglitazone. Both the control and DN MKK3
cells exhibited low basal levels of PPARQ mRNA, as seen in
the untreated lanes (Fig. 2). The control C2C12 cells did not
show an increase in PPARQ mRNA upon treatment with ro-
siglitazone. In contrast, a dramatic increase in PPARQ mRNA
was seen in the DN MKK3 cells. There appeared to be two
closely migrating bands in the rosiglitazone-treated lane, cor-
responding to the mRNA of the two di¡erent isoforms,
PPARQ1 and PPARQ2. The high levels of PPARQ mRNA
may re£ect the large numbers of adipocytes present in the
DN MKK3 cells after rosiglitazone treatment.
Analysis of protein extracts from the control and DN
MKK3 cells by Western blotting revealed the expression of
the adipocyte-speci¢c marker aP2 in the DN MKK3 cells
after 5 days treatment with rosiglitazone (Fig. 3A). In addi-
tion, levels of aP2 expression appeared to increase in a dose-
responsive manner with increasing rosiglitazone concentration
(Fig. 3B). No aP2 protein was detected in protein extracts
from control cells. In contrast, the control extracts contained
high levels of myogenin, re£ecting their myogenic phenotype
(Fig. 3A). The levels of myogenin were the same with and
without rosiglitazone treatment, suggesting that treatment
with rosiglitazone had no e¡ect on the expression of this
myogenic marker. The DN MKK3 cells expressed negligible
amounts of myogenin, in keeping with their lack of ability to
di¡erentiate into myotubes [16].
3.3. Use of the inhibitors SB203580 and PD98059 do not a¡ect
the ability of C2C12 cells to di¡erentiate into adipocytes
In light of the potential role played by the MKK3/p38 path-
way in the trans-di¡erentiation of C2C12 cells into adipocytes,
we decided to test the e¡ects of the p38 inhibitor SB203580 on
these cell lines. The extracellular signal-regulated kinase inhib-
itor PD98059 was included for comparison. We initially veri-
¢ed the e¡ectiveness of the SB203580 compound in inhibiting
p38 activity through the use of kinase assays (results not
shown). We used the inhibitors SB203580 and PD98059
with and without rosiglitazone treatment of the cells. The
inclusion of SB203580 in the medium along with rosiglitazone
prevented myotube formation in control cells, but did not
ameliorate adipogenesis. The addition of PD98059 plus rosi-
glitazone did not a¡ect myotube formation or adipogenesis in
control cells. The presence or absence of adipocytes was re-
£ected by aP2 protein expression levels (Fig. 4). In the DN
Fig. 2. Expression of PPARQ mRNA in C2C12 control and MKK3
DN cells. RNA was harvested from untreated cells, and cells treated
with 5 WM rosiglitazone (BRL) from 2 days before con£uence to
5 days post-con£uence, and analyzed by Northern blotting using a
PPARQ insert as a probe. RNA was harvested at day 5 post-con£u-
ence.
Fig. 3. Expression of adipogenic markers by MKK3 DN C2C12
cells in response to rosiglitazone treatment. A: Protein extracts were
harvested from cells after treatment with 5 WM rosiglitazone for up
to 5 days post-con£uence, and analyzed by immunoblotting using
antibodies against the adipogenic protein aP2 and the myogenic
protein myogenin. B: The dose-dependence of aP2 protein expres-
sion upon rosiglitazone concentration. Control and MKK3 DN
C2C12 cells were treated with increasing concentrations of rosiglita-
zone from 2 days before con£uence to 5 days post-con£uence. Pro-
tein extracts were harvested at day 5, and analyzed by immunoblot-
ting with a monoclonal anti-aP2 antibody. The intensity of the
bands were quanti¢ed using PCBas0, and expressed as arbitrary
units. Error bars represent the standard deviation of three indepen-
dent experiments with three separate clones of each cell line.
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MKK3 cells, addition of either SB203580 or PD98059 along
with rosiglitazone did not a¡ect the ability of these cells to
trans-di¡erentiate (not shown). Similar amounts of aP2 pro-
tein were expressed in DN MKK3 cells treated with rosiglita-
zone, with and without SB203580 and PD98059 (Fig. 4).
3.4. Treatment of the DN MKK3 cells with the PI3 kinase
inhibitor, LY294002, inhibits adipogenic trans-
di¡erentiation of the DN MKK3 cells
We next asked whether the PI3 kinase pathway was in-
volved in the trans-di¡erentiation of the DN MKK3 cells
into adipocytes, as this pathway is known to be important
in adipogenesis [20]. As previously shown, control cells failed
to di¡erentiate into myotubes upon treatment with the PI3
kinase inhibitor LY294002 [21]. No adipocytes or lipid drop-
lets were present in control cells upon treatment with rosigli-
tazone plus LY294002 (not shown). In contrast, treatment of
the DN MKK3 cells with LY294002, along with rosiglitazone,
caused a signi¢cant decrease in the number of adipocytes after
5 days post-con£uence (Fig. 5). The decrease in the level of
adipocytes in the DN MKK3 cells is also re£ected by a
marked reduction in aP2 expression levels (Fig. 5).
Since the protein kinase Akt is known to act downstream of
PI3 kinase, we tested C2C12 cells stably overexpressing DN or
constitutively active (CA) Akt [21] for their ability to trans-
di¡erentiate into adipocytes (results not shown). However,
treatment of these cell lines with rosiglitazone did not result
in adipocytic trans-di¡erentiation. No increase in the levels of
PPARQ mRNA or aP2 protein were detected (results not
shown). This suggests that the ability of C2C12 cells to
trans-di¡erentiate into adipocytes requires a functional PI3
kinase pathway, but the downstream kinase Akt appears not
to be involved.
A general summary of our ¢ndings is depicted in Fig. 6.
4. Discussion
We demonstrate that the inhibition of myogenesis, via the
expression of a DN MKK3, enhances the trans-di¡erentiation
of C2C12 cells into adipocytes in response to rosiglitazone
treatment. In addition, the adipogenic e¡ects of rosiglitazone
on DN MKK3 cells are re£ected by an increase in PPARQ.
Adipocyte formation was demonstrated by the presence of
clusters of rounded cells, containing lipid droplets that stained
with Oil red O, and the expression of the adipocyte lipid
binding protein aP2. All results were veri¢ed using three sep-
arate clones of each cell line.
Several reports have been published on the capacity of the
C2C12 cell line to trans-di¡erentiate into various lineages.
Treatment of a naturally G418-resistant subclone of this cell
line, C2C12N, with thiazolidinediones and fatty acids results
in their conversion into adipose-like cells [22]. In contrast to
Fig. 4. Treatment of control and DN MKK3 C2C12 cells with dif-
ferent MAP kinase inhibitors does not a¡ect their abilities to trans-
di¡erentiate into adipocytes upon treatment with rosiglitazone. Cells
were grown in the presence of rosiglitazone alone, or in combina-
tion with the inhibitors SB203580 and PD098059 from 2 days be-
fore con£uence up to 5 days post-con£uence. Protein extracts were
harvested at day 5, and analyzed for expression of aP2.
Fig. 5. The PI3 kinase inhibitor LY294002 impedes the trans-di¡erentiation of the MKK3 DN C2C12 cells into adipocytes upon rosiglitazone
treatment. Upper part: DN MKK3 cells were treated with either 5 WM rosiglitazone alone, or in combination with 10 WM LY294002, for up
to 5 days post-con£uence. Lower part: Protein extracts were harvested from control and DN MKK3 cells at day 5 and analyzed for aP2 pro-
tein expression by immunoblotting. Scale bar = 10 Wm.
FEBS 25297 28-9-01
K. Yeow et al./FEBS Letters 506 (2001) 157^162160
this report on adipogenic trans-di¡erentiation of the C2C12N
cell line, our study demonstrates that wild-type and control
C2C12 cells stably transfected with the empty vector do not
respond e⁄ciently to rosiglitazone treatment. It is important
to note that our study was based on wild-type C2C12 cells ;
the C2C12N cell line was originally isolated as a G418-resis-
tant subclone of C2C12 cells. Thus, the di¡erence in the abil-
ity of C2C12N versus C2C12 cells to form adipocytes in re-
sponse to rosiglitazone treatment could be due to inherent
genetic di¡erences between these two cell lines.
Interestingly, treatment of the control C2C12 cells with the
p38 inhibitor SB203580 followed by rosiglitazone stimulation,
did not result in increased numbers of adipocytes. There are
several possible explanations for this. First, the SB203580 in-
hibitor is thought to directly block the activation of p38 [23],
which is the downstream target of MKK3. Thus, should
MKK3 a¡ect adipogenesis independently of p38, the use of
this inhibitor would have no obvious e¡ects on adipogenic
trans-di¡erentiation. In addition, short-term treatment of cells
with an inhibitor cannot be compared to long-term, stable
overexpression of a DN construct. Therefore, although ex-
pression of DN MKK3 and treatment of C2C12 cells with
SB203580 have similar outcomes on myogenesis [14,24], one
cannot assume that the use of SB203580 has actions equiva-
lent to that of stable expression of DN MKK3 in the context
of trans-di¡erentiation into adipocytes.
The expression of DN MKK3 is known to block myogen-
esis, in particular, the process of myotube formation [16]. It is
possible that inhibiting myogenesis in these cells facilitates
adipocytic trans-di¡erentiation by enabling them to respond
to other di¡erentiation agents. Ectopic expression of msx1, a
nuclear protein thought to play a role in urodele cellular de-
di¡erentiation, in di¡erentiated C2C12 myotubes abrogates
the di¡erentiated phenotype and results in a dedi¡erentiated
population of cells capable of expressing chondrocytic, osteo-
genic, myogenic, and adipogenic markers [25]. Our results
with the DN MKK3 cells extends previous work on the plas-
ticity of this myogenic cell line, in that expression of a kinase-
inactive form of MKK3 is su⁄cient to enable adipogenic
trans-di¡erentiation, possibly as an indirect result of its ability
to inhibit the normal process of myogenesis.
The adipocytic trans-di¡erentiation of the DN MKK3 cells
involves the upregulation of PPARQ mRNA. In ¢broblastic
cell lines, ectopic expression of PPARQ is su⁄cient to initiate
adipogenesis [10]. Thiazolidinediones can act as ligands by
directly binding and activating PPARQ [26], which then leads
to the induction of genes involved in fatty acid uptake, stor-
age, and metabolism, including aP2 [13,27^29]. This increase
in PPARQ can be perpetuated via C/EBPK, which in turn
further activates PPARQ expression [30]. In the case of the
DN MKK3 C2C12 cells, activation of the low basal levels
of PPARQ could lead to adipocytic trans-di¡erentiation, in
turn leading to elevated levels of PPARQ in a positive-feed-
back manner.
Interestingly, the ability of the DN MKK3 cells to form
adipocytes in response to rosiglitazone treatment was drasti-
cally inhibited by the PI3 kinase inhibitor LY294002. The PI3
kinase [20,31] pathway is known to be extremely important
for adipocytic di¡erentiation. Thus, it is not surprising that
LY294002 inhibited the formation of adipocytes in the DN
MKK3 cells. However, treatment of C2C12 cells stably over-
expressing DN Akt and CA Akt with rosiglitazone did not
result in the formation of adipocytes, precluding the involve-
ment of Akt. It is possible that this process of trans-di¡er-
entiation involves other e¡ectors of PI3 kinase besides Akt,
such as the atypical protein kinase C (PKC) molecules, PKCV
and PKCj [32,33]. It is known that insulin is able to activate
the atypical PKCs through PI3 kinase-dependent increases in
phosphatidylinositol-3,4,5-phosphate [34], and that thiazolidi-
nedione treatment can enhance these e¡ects [35]. Further
work will be necessary in order to unravel the inter-relation-
ships between these two signalling pathways in the trans-dif-
ferentiation of myoblasts into adipocytes.
In summary, we show that inhibition of myogenesis via
expression of DN MKK3 enables C2C12 myoblastic cells to
trans-di¡erentiate into adipocytes upon treatment with rosi-
glitazone. This process involves the upregulation of PPARQ,
and may involve signalling via the PI3 kinase pathway.
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